Leqvio® (Inclisiran)

Referring Provider Order Form – For Use with Participating Infusion Centers Rev. 09/2025

Please send completed referral form & all required documents to referrals@healix.net or fax to 281-295-4086



Patient Name:
Allergies:
INSURANCE INFORMATION: Please attach copy of insurance card (front and back). DIAGNOSIS*
I25.10
125.10
**ICD 10 Code
Required
Other:
INFUSION ORDERS MEDICATION Leqvio®(Inclisiran) 284 mg INITIAL: First dose: Inject SubQ x 1 dose. Second dose at 3 months: Inject SubQ x 1 dose. Second dose at 3 months: Inject SubQ x 1 dose. MAINTENANCE: Inject SubQ every 6 months x 1 year. Is patient currently receiving therapy above from another facility? Date of last treatment: Date of next treatment: PRE-MEDICATION ORDERS LAB ORDERS No premeds ordered at this time Acetaminophen 650mg PO Other: No labs ordered at this time Other:
MEDICATION DOSE DIRECTIONS/DURATION
Second dose at 3 months: Inject SubQ x 1 dose. MAINTENANCE: Inject SubQ every 6 months x 1 year. Is patient currently receiving therapy above from another facility? NO YES Date of last treatment: Date of next treatment:
Second dose at 3 months: Inject SubQ x 1 dose. MAINTENANCE: Inject SubQ every 6 months x 1 year. Is patient currently receiving therapy above from another facility? NO YES Date of last treatment: Date of next treatment: PRE-MEDICATION ORDERS LAB ORDERS No premeds ordered at this time Labs to be drawn by: Infusion Center Referring Physician Acetaminophen 650mg PO Other: No labs ordered at this time Other:
If yes, Facility Name:
another facility? Date of last treatment: Date of next treatment: PRE-MEDICATION ORDERS LAB ORDERS Labs to be drawn by: No premeds ordered at this time Acetaminophen 650mg PO Other: No labs ordered at this time Other:
□ NO □ YES Date of last treatment:
□ No premeds ordered at this time □ Acetaminophen 650mg PO □ Other: □ No labs ordered at this time □ No labs ordered at this time □ Other:
□ Acetaminophen 650mg PO □ Other: □ No labs ordered at this time □ Other:
Diphophydromino 25mg PO
□ Diphenhydramine 25mg PO □ LDL-C q □ Lipid Panel q □ LFTs q □ LFTs q
REFERRING PHYSICIAN INFORMATION
Physician Signature: Date:
Physician Name: Provider NPI: Specialty:
Address: City/ST/Zip:
Contact Person:
Email Where Follow Up Documentation Should Be Sent:
REQUIRED CLINICAL DOCUMENTATION
Please attach medical records: Initial H&P, current MD progress notes, medication list, and labs/test results to support diagnosis.
For all diagnoses: ☐ Yes ☐ No Does the patient have elevated LDL-C level?
Recent LDL-C level: mg/dL; Date lab drawn: (Attach copy of labwork)
☐ Yes ☐ No Is the patient currently on statin therapy?
Current statin therapy; Drug name: Dosage: Start date or Length of Therapy:
 ☐ Check box if patient is on Zetia[®] (ezetimibe) in addition to statin therapy. If No, please specify: ☐ Patient is statin intolerant (list failed statin therapies and reasons below)
□ Patient has a contraindication for statin therapy, specify:
□ Other:
☐ Yes ☐ No Has the patient been compliant with lipid lowering drug therapy and lifestyle modifications?
For ASCVD only: History of clinical atherosclerotic cardiovascular disease includes one of more of the following: (Select all that apply)
☐ Acute coronary syndrome ☐ Stable or unstable angina ☐ Transient ischemic attack (TIA)
☐ Coronary artery disease (CAD) ☐ Coronary or other arterial revascularization ☐ Peripheral arterial disease (PAD)
☐ History of myocardial infarction (MI) ☐ Stroke ☐ Other:
For HeFH only: HeFH confirmed by: ☐ Mutation in LDLR, ApoB, PCSK9, or ARH adaptor protein(LDLRAP1) gene (Attach copy of test results)
☐ WHO/Dutch Lipid Clinic Network Score (DLCNS); Score: (Attach copy of assessment)
□ Other:
LAB RESULTS (required)
□ LDL cholesterol blood level
PRIOR FAILED THERAPIES (including statins and PCSK9 inhibitors)
Madigation: Dates of Treatment: December 170
Medication: Dates of Treatment: Reason for D/C:
Medication: